Background
PrEP Fact Sheet (PDF) - July 2012PrEP Trials Table (PDF) - April 2012
PrEP Trials Timeline (PDF, JPG) - May 2011
PrEP Trials Map (PDF, JPG) - May 2012
PrEP Primer (PDF) - February 2011
PrEP using daily oral TDF/FTC or TDF in Women (and Men): What the science tells us (PDF) - September 2012
"Connecting the Dots" PrEP trials table - (PDF, JPG) - February 2011
What PrEP is and What PrEP is not - (PDF) - March 2011
The PrEP fact sheet (PDF) is also available in Arabic, Chinese, French, Portuguese, Russian, Spanish and Thai. These versions were last updated in October 2010.
Guidance on PrEP Usage
World Health
Organization
US Centers for Disease
Control
The British HIV Association/British
Association for Sexual Health and
HIV
Southern African HIV Clinicians
Society Consensus Committee
PrEP-related webinars and teleconferences
- VOICE Trial Results and Implications for Future Research - March 11, 2013
- Conference
on Retroviruses and Opportunistic
Infections - March 3, 2013
- Beyond
Daily Oral TDF/FTC as PrEP: Exploring new drugs
and regiments for PrEP - October 3,
2012
- New
Guidance on Daily Oral PrEP: What's out there
and what does it mean for advocates -
September 18, 2012
- The
HIV Prevention Pipeline: A future of
possibilities - August 23,
2012
Earlier webinars and
teleconferences are available at www.avac.org/meetingreports.
Additional materials
ACHIEVE — A Quarterly Journal on HIV Prevention, Treatment and Politics
Rectal Microbicides: How do we rethink decades of prevention programs that equated condoms with safer sex and left few other choices?
A Cascade of Hope and Questions is a two-part series (part of AVAC's Anticipating and Understanding Results series) designed to help advocates prepare for the issues raised by recent and upcoming results from ARV-based prevention trials.
- Volume 2: Understanding the results of CAPRISA 004 - August 2010
- Volume 1: Anticipating results of ARV-based HIV prevention trials - July 2010
PrEP at CROI 2011 - ARV-based Prevention: A community and research forum on recent results and what happens next
Interim Guidance on PrEP -
Organizations are beginning to offer interim guidance to health care providers on PrEP as an HIV prevention strategy for gay men and other men who have sex with men.
iPrEx Trial Update - (Q1 2009), (Q2 2009), (Q3 2010), (Q4 2010)
These updates provided trial information and community perspectives on the iPrEx trial while it was ongoing. Visit the iPrEX webpage to find these resources in other languages.
Funding for PrEP R&D in 2010 - HIV Vaccines and Microbicides Resource Tracking Working Group - July 2011
Taking it to the Streets: Engaging in-country stakeholders to plan for possible PrEP implementation - PDF, May 2010
FEM-PrEP Trial Newsletter - (Issue 2 - July 09), (Issue 1 - January 09)
The FEM-PrEP clinical trial is led by Family Health International (FHI) and is designed to test the safety and effectiveness of Truvada for HIV prevention. The FEM-PrEP Trial newsletter provides news and updates on the trial progression.
Consultation
on the Intermittent PrEP (iPrEP) Research
Agenda - Summary of a think tank sponsored by
amfAR and AVAC, December 2009
AVAC and amfAR convened a one-day meeting of
leaders from research and research sponsor
agencies to review the status of biomedical,
behavioral and animal research relevant to
iPrEP, identify gaps in this research, and
suggest priorities for moving forward.
PrEP: What does it mean for
women?
Fact sheet - Global Campaign for Microbicides,
August 2009
PrEP 101 Slide set - May 2009
The PrEP Implementation Puzzle: Many missing pieces, AVAC Report 2009 - May 2009
Part of the Solution: Setting
expectations for WHO and UNAIDS
AVAC Report May
2009
Research Rashomon: Lessons from the Cameroon Pre-exposure Prophylaxis Trial Site - Global Campaign for Microbicides, May 2009
Preventing Prevention Trial Failures: A Case Study and Lessons for Future Trials from the 2004 Tenofovir Trial in Cambodia - Global Campaign for Microbicides, May 2009
Oral Tenofovir Controversy II. Report of the tenofovir controversy from the perspectives of the community voices from the field - New HIV Vaccine and Microbicide Advocacy Society, April 2009
A Lexicon of Intermittent PrEP
Possibilities - PrEP Committee
Research Working Group, February 2009
"Pre-Exposure Prophylaxis:
Could It Work?" - Sharon Hillier's
plenary at CROI 2009, February 2009
Preparing for PrEP: Policy,
Practice and Politics
Colleagues from multiple disciplines
met for a one-day, AVAC-sponsored think tank
examining how PrEP for HIV prevention might be
funded or reimbursed through insurance
mechanisms in the United States should it prove
safe and effective. The think tank took forward
discussions on PrEP implementation strategies
by identifying key regulatory, legal, and
financial challenges to PrEP
implementation.
Meeting Summary for Trials of
Intermittent Dosing of Pre-Exposure Prophylaxis
(PrEP)
- AVAC Think
Tank, December
2008
In
December 2008, AVAC held a one-day think tank
where colleagues from multiple agencies and
research disciplines discussed key scientific
questions to be addressed in evaluating the
merits of future prevention research on
intermittent use of pre-exposure prophylaxis
(“iPrEP”) for prevention of
HIV.
Anticipating/Understanding
results from PrEP trials (English
and
Spanish)
-
August 2008
This report provides background on
PrEP research, the status of current clinical
trials, and issues concerning effective
delivery should PrEP prove effective. It closes
with a list of priority issues that need
attention from governments, global health
institutions, donors, researchers, and
advocates.
Expecting
(and managing) the unexpected: Reality check
for PrEP and other new prevention
options - Preparing for PrEP: Policy, Practice
and Politics August 2008
The bulk of
the session was devoted to a scenarios-based
discussion in which panelists were asked to
comment on issues while considering a range of
possible results.